In this article, we will discuss the 12 Best Get Rich Quick Stocks to Buy According to Hedge Funds.

On March 9, Main Management CEO and Portfolio Manager Kim Arthur joined CNBC’s ‘Halftime Report’ to talk about what he’s seeing in his sector rotation fund, and whether the volatility is exacerbating that trend or reversing it amid the turmoil in the Middle East. Arthur explained that a major mix shift began in the market last October. He described this shift as a move away from asset-light sectors (specifically technology, communications, and consumer discretionary) and toward asset-heavy sectors (including basic materials, industrials, and energy). He used a physical analogy for these asset-heavy plays and noted they consist of items from the periodic table that would cause physical pain if dropped on one’s toe.

Despite the recent sidetrack caused by the attacks and war in the Middle East involving Iran, Arthur maintained that the rotation thesis remains intact. He highlighted that asset-heavy plays have significantly outperformed asset-light sectors, leading them by approximately 15 points year-to-date. He believes that once the immediate geopolitical conflict passes, this trend will continue. Regarding the future of the tech trade and whether investors will return to it out of muscle memory, Arthur clarified that tech is not dead and expects it to perform okay. However, he emphasized that the cycle favoring asset-heavy plays is likely to be long-dated. He attributed this longevity to structural trends such as the massive build-out of data centers, the on-shoring of manufacturing, and the physical requirements of buying land and putting steel in the ground.

That being said, we’re here with a list of the 12 best get-rich-quick stocks to buy according to hedge funds.

Our Methodology

We sifted through financial media reports to compile a list of stocks discussed for making you rich, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Note: All data was sourced on March 13. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

12 Best Get Rich Quick Stocks to Buy According to Hedge Funds

12. Bicycle Therapeutics (NASDAQ:BCYC)

Number of Hedge Fund Holders: 23

Bicycle Therapeutics (NASDAQ:BCYC) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 3, Bicycle Therapeutics announced several key leadership transitions as the company enters a new phase of innovation for its proprietary bicyclic peptide technology. Travis Thompson, who joined the firm in 2018 and previously served as senior vice president and chief accounting officer, has been appointed as the new chief financial officer. He succeeds Alethia Young, who will transition into an advisory role after a three-month interim period. Thompson’s new responsibilities include overseeing finance, accounting, and investor relations.

In the clinical and scientific departments, Michael Method, M.D., MPH, MBA, has been promoted to chief medical officer, taking over for Eric Westin, M.D., who is retiring from the role. Dr. Method, an oncologist who joined the company in 2025, will now lead clinical development and manage the Clinical Advisory Board. Additionally, Michael Skynner, Ph.D., a veteran of the company since 2016, is moving from his role as chief technology officer to become the chief scientific officer. Dr. Skynner will focus on scientific discovery, early-stage pipeline development, and the Research & Innovation Advisory Board.

CEO Kevin Lee, Ph.D., stated that these leadership changes are intended to build momentum across the company’s oncology pipeline and create shareholder value following significant progress in 2025. The company highlighted its strengthened operational capacity and a financial runway expected to last into 2028. Moving forward, the executive team aims to advance targeted oncology clinical programs and recently established radiopharmaceutical strategic partnerships to improve patient outcomes.

Bicycle Therapeutics (NASDAQ:BCYC) is a clinical-stage pharmaceutical company that develops a class of medicines for diseases that are underserved by existing therapeutics in the US and the UK.

11. ACM Research Inc. (NASDAQ:ACMR)

Number of Hedge Fund Holders: 32

ACM Research Inc. (NASDAQ:ACMR) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 26, ACM Research achieved record annual revenue of $901.3 million in 2025, representing a 15% increase year-over-year. This was driven by a cleaning portfolio and the expansion of proprietary technologies like high-temperature furnace platforms. While full-year revenue was strong, Q4 saw a more moderate revenue increase of 9.4% to $244.4 million.

2025 was a year of geographic and product expansion. ACM made progress in global markets, delivering its first single-wafer cleaning systems to a foundry in Singapore and securing multiple orders for wafer-level and panel-level packaging tools from North American and Southeast Asian customers. The company also reached technical milestones with the delivery of its first Ultra ECP ap-p horizontal panel-level plating tool and the Ultra Lith BK photoresist hardening tool. To support this global scaling, ACM is accelerating investments in its Oregon facility, expected to begin operations in H2 2026.

The company entered 2026 with a strengthened balance sheet, reporting $845 million in net cash following a private offering by its Shanghai subsidiary and a subsequent share sale in early 2026. Looking ahead, ACM Research Inc. (NASDAQ:ACMR) maintained its 2026 revenue guidance of $1.08 billion to $1.175 billion, projecting growth between 21% and 30%.

ACM Research Inc. (NASDAQ:ACMR), together with its subsidiaries, develops, manufactures, and sells capital equipment in Mainland China and internationally. It also develops, manufactures, and sells a range of packaging tools to wafer assembly and packaging customers.